Income Tax Expense (Benefit) in USD of NEVRO CORP from 2012 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
NEVRO CORP quarterly/annual Income Tax Expense (Benefit) history and change rate from 2012 to Q4 2024.
  • NEVRO CORP Income Tax Expense (Benefit) for the quarter ending 31 Dec 2024 was $169,000.000.
  • NEVRO CORP Income Tax Expense (Benefit) for the twelve months ending 31 Dec 2024 was $1,093,000.000.
  • NEVRO CORP annual Income Tax Expense (Benefit) for 2024 was $1,093,000.000.
  • NEVRO CORP annual Income Tax Expense (Benefit) for 2023 was -$5,646,000.000, a 547% decline from 2022.
  • NEVRO CORP annual Income Tax Expense (Benefit) for 2022 was $1,263,000.000, a 137% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

NEVRO CORP Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $1,093,000 $169,000 +$6,747,000 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025
Q3 2024 -$5,654,000 $280,000 +$150,000 +1.2% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024
Q2 2024 -$5,804,000 $262,000 -$215,000 -45.1% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024
Q1 2024 -$5,589,000 $382,000 +$57,000 +17.5% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2024
Q4 2023 -$5,646,000 -$6,578,000 -$6,934,000 -19.5% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025
Q3 2023 $1,288,000 $130,000 -$355,000 -73.2% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 $1,643,000 $477,000 +$236,000 +97.9% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024
Q1 2023 $1,407,000 $325,000 +$144,000 +79.6% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q4 2022 $1,263,000 $356,000 +$434,000 01 Oct 2022 31 Dec 2022 10-K 04 Mar 2025
Q3 2022 $829,000 $485,000 +$413,000 +5.7% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023
Q2 2022 $416,000 $241,000 +$43,000 +21.7% 01 Apr 2022 30 Jun 2022 10-Q 01 Aug 2023
Q1 2022 $373,000 $181,000 -$161,000 -47.1% 01 Jan 2022 31 Mar 2022 10-Q 26 Apr 2023
Q4 2021 $534,000 -$78,000 -$388,000 -1.3% 01 Oct 2021 31 Dec 2021 10-K 23 Feb 2024
Q3 2021 $922,000 $72,000 -$136,000 -65.4% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022
Q2 2021 $1,058,000 $198,000 +$154,000 +3.5% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022
Q1 2021 $904,000 $342,000 +$36,000 +11.8% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022
Q4 2020 $868,000 $310,000 -$171,000 -35.6% 01 Oct 2020 31 Dec 2020 10-K 21 Feb 2023
Q3 2020 $1,039,000 $208,000 -$212,000 -50.5% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 $1,251,000 $44,000 -$314,000 -87.7% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021
Q1 2020 $1,565,000 $306,000 -$34,000 -10% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021
Q4 2019 $1,599,000 $481,000 +$990,000 01 Oct 2019 31 Dec 2019 10-K 23 Feb 2022
Q3 2019 $609,000 $420,000 -$131,000 -23.8% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 $740,000 $358,000 -$25,000 -6.5% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020
Q1 2019 $765,000 $340,000 -$3,000 -0.88% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020
Q4 2018 $768,000 -$509,000 -$901,000 -2.3% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021
Q3 2018 $1,669,000 $551,000 +$177,000 +47.3% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019
Q2 2018 $1,492,000 $383,000 +$2,000 +0.52% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 $1,490,000 $343,000 +$82,000 +31.4% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 $1,408,000 $392,000 -$191,000 -32.8% 01 Oct 2017 31 Dec 2017 10-K 25 Feb 2020
Q3 2017 $1,599,000 $374,000 -$74,000 -16.5% 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018
Q2 2017 $1,673,000 $381,000 +$123,000 +47.7% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018
Q1 2017 $1,550,000 $261,000 -$73,000 -21.9% 01 Jan 2017 31 Mar 2017 10-Q 07 May 2018
Q4 2016 $1,623,000 $583,000 -$17,000 -2.8% 01 Oct 2016 31 Dec 2016 10-K 21 Feb 2019
Q3 2016 $1,640,000 $448,000 +$179,000 +66.5% 01 Jul 2016 30 Sep 2016 10-Q 06 Nov 2017
Q2 2016 $1,461,000 $258,000 +$103,000 +66.5% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017
Q1 2016 $1,358,000 $334,000 +$192,000 +1.4% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017
Q4 2015 $1,166,000 $600,000 +$496,000 +4.8% 01 Oct 2015 31 Dec 2015 10-K 22 Feb 2018
Q3 2015 $670,000 $269,000 +$132,000 +96.4% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016
Q2 2015 $538,000 $155,000 +$11,000 +7.6% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016
Q1 2015 $527,000 $142,000 +$49,000 +52.7% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q4 2014 $478,000 $104,000 01 Oct 2014 31 Dec 2014 10-K 23 Feb 2017
Q3 2014 $137,000 +$6,000 +4.6% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015
Q2 2014 $144,000 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015
Q1 2014 $93,000 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015
Q3 2013 $131,000 01 Jul 2013 30 Sep 2013 10-Q 02 Dec 2014

NEVRO CORP Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1,093,000 +$6,739,000 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025
2023 -$5,646,000 -$6,909,000 -5.5% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025
2022 $1,263,000 +$729,000 +1.4% 01 Jan 2022 31 Dec 2022 10-K 04 Mar 2025
2021 $534,000 -$334,000 -38.5% 01 Jan 2021 31 Dec 2021 10-K 23 Feb 2024
2020 $868,000 -$731,000 -45.7% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023
2019 $1,599,000 +$831,000 +1.1% 01 Jan 2019 31 Dec 2019 10-K 23 Feb 2022
2018 $768,000 -$640,000 -45.5% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021
2017 $1,408,000 -$215,000 -13.2% 01 Jan 2017 31 Dec 2017 10-K 25 Feb 2020
2016 $1,623,000 +$457,000 +39.2% 01 Jan 2016 31 Dec 2016 10-K 21 Feb 2019
2015 $1,166,000 +$688,000 +1.4% 01 Jan 2015 31 Dec 2015 10-K 22 Feb 2018
2014 $478,000 +$116,000 +32% 01 Jan 2014 31 Dec 2014 10-K 23 Feb 2017
2013 $362,000 +$200,000 +1.2% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016
2012 $162,000 01 Jan 2012 31 Dec 2012 10-K 18 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.